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Structure activity relationships (SAR) published in journals underpin medicinal chemistry.  
However, patents contain more SAR data and surface years earlier.  While their documents 
present challenges for data mining, there has been a recent “big bang” in the availability of 
extracted chemistry in open databases.  Consequently, PubChem now contains ~20 million 
structures from patents, including most of those associated with bioactivity.  This chapter 
covers a selection of resources, tools and tricks that can be used to dig out patent SAR.  It 
also explores intersects between chemistry curated from papers by ChEMBL and 
automatically extracted from patents by SureChEMBL.  
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This chapter will present examples of interrogating medicinal chemistry patent sources with 
the primary objective of digging out structure activity relationships (SAR). Since the details 
below will show this to be more difficult than for papers why bother?  The main reasons are 
that patents not only contain more SAR but also that is published earlier.  Statistics in support 
of both these advantages are difficult to obtain but will be partially addressed below. For 
discrete SAR values a conservative estimate of at least two-fold more data-mapped structures 
in patents can be made. If ranged values are included the difference rises to at least five-fold. 
In support of this, it was reported in 2011 that Factor IXa (F10, P00742) had 5.8K assayed 
compounds mapped to it via extracted from papers by ChEMBL but this had increased to 
43K from combined literature and patent extractions by GVKBIO (i.e. papers: patents ~1: 6) 
[1].  The time advantage is more difficult to support with data but it is well known that 
pharmaceutical company drug discovery teams typically wait two to three years after a patent 
application before publishing in a journal. In some cases, high quality project results will be 
exemplified as substantial SAR sets in patents but may never surface elsewhere.   
 
As an important adjunct to SAR extraction per se this chapter will also exemplify ways of 
exploring connectivity between papers and patents from the same teams.  However, both 





 Commercial sources, even just major ones, now present too broad a spectrum of 
technical features to review (i.e. no author would have either the multiple licences or 
capacity for detailed comparative evaluation).  
 
 There has been a remarkable “big bang” in the availability of automated patent-
extracted chemistry just in the last few years, culminating in the secondary deposition 
of ~ 19 million patent-derived entries in PubChem and primary extraction of ~ 17 
million of these into SureChEMBL [2]  
 
 This has led to a democratisation of patent mining that has now become more 
accessible for those without commercial databases or tools.  
 
 Concomitantly, parallel interrogation of open resources has become essential for users 
of commercial databases anyway, since the inevitable divergence of coverage by 
different sources precludes any one-stop-shop. 
 
 PubChem precomputes relationships between 2D and 3D chemical structures, patent 
documents, PubMed IDs, PDB entries, bioassay results and annotation from many 
curated submitting sources [3]. This means that the combined PubChem and Entrez 
functionality now encompasses the majority of bioactive patent chemistry. This thus 
presents a scale of relationship navigation that closed commercial databases cannot 
match.   
 
Although aspects of intellectual property (IP) focused searching and/or competitive 
intelligence (CI) analysis will only briefly be touched upon, strategically they may be better 
addressed by commercial databases, depending on what value-added features they offer for 
these two domains. This may include enhancing the indexing depth and precision of public 
data in various ways, including manual annotation.   
 
Additional caveats related to the coverage of this chapter need mentioning.  The first is that 
the techniques exemplified here are small-scale, largely manual and thus more individual 
orientated exercises rather than large scale approaches. The second coverage restriction is 
that illustrative examples can only be accompanied by short technical descriptions, although 
they will be referenced for users to access the details.  The third is that the queries describe 
here we executed in September of 2016 and may thus give different results at later dates. The 
fourth is that, particularly in the patent domain, queries are rarely “clean” in terms of 
specificity or recall (some of the reasons for this will be discussed).  The ones used here are 
presented in good faith with the expectation of some level of reproducibility. However, they 
can be disconcertingly noisy and inconsistent in practice.  One reason is that patent offices 
and other sources often do not index document metadata in standardised ways (e.g. conflating 
applicants with inventors or multiple synonyms for the same applicant institutions).  Another 
is that different interfaces to nominally the same document corpora can give different results 
(e.g. depending on the filtration options selected and the syntax used for complex queries).  
The fifth caveat is that while queries executed here have been designed to reflect real-world 
tasks they are also somewhat contrived for illustrative purposes and thus may not be the most 
efficient way to get to the explicit results.  There are many choices of entry points, tools, 
query strategies and technical tricks that may answer particular questions more quickly.  
 




1. With the exception of a few novel structures not yet submitted to any public databases 
specifically mentioned compounds will be specified either by a PubChem Compound 
Identifier or a Substance Identifier or in some cases both.   
 
2. Rather than necessitate the addition of many hyperlinks into the text, each of these 
can be accessed via two standard URLs.  For example, atorvastatin,  as CID 60823 
can be linked out as https://pubchem.ncbi.nlm.nih.gov/compound/60823.  The 
specific submission from SureChEMBL, SID 226395935, can be analogously linked 
as https://pubchem.ncbi.nlm.nih.gov/substance/226395935.   
 
3. There are too many patents to be fully referenced so their numbers are specified in the 
text. These will usually retrieve links to the document in the upper ranks of a Google 
search result within seconds.    
 
4. SAR retrievals will focus on beta-secretase 1 (BACE1, Swiss-Prot P56817) as an 
Alzheimer’s disease (AD) protease [4].   The illustrative advantages of an intensively 
pursued drug target will become apparent as we track through over a decade of 
substantial SAR and explore patent-to-patent and patent-to-paper connections.   
 
5. For reasons of space, a basic familiarity with querying databases and patents has to be 
assumed. In particular this should include patent office websites (e.g. EPO Espacenet, 
USPTO and WIPO), kind codes (A1, B2 etc.)  patent classifications, the concept of 
patent family and experience with searching in PubChem or other chemistry portals.   
 
Statistics of extractable SAR 
 
The complex task of extracting chemical and biological entities from patents has been well 
studied.  Some of the different approaches will be referred to below but the complication is 
that SAR is defined by relationships between entities.  For this reason, questions regarding 
SAR statistics both inside and outside patents are difficult to get precise answers to but would 
be useful for making judgments on what is realistically achievable.    
 
In this context it is useful to review our high level assumptions.  The first is that readers have 
an interest in bioactive chemistry in the wider sense, with the obvious proviso that very low 
or inactivity is crucial for SAR and control experiments but data sets are biased towards 
activity and potent compounds.  The second would be that, regardless of the dominance of 
medicinal chemistry,  IP domains related to tropical diseases,  antivirals, antibiotics  
herbicides, pesticides,  toxicology and chemical biology can  be approached for SAR mining 
in broadly the same ways as described here for human target-centric drug discovery.  It is 
also a reasonable assumption that medicinal chemists have at least some interest in extracted 
structures that were not designed to have biological effects  per se (e.g. novel reactions, 
dyestuffs, photochemistry etc) but where the documented synthetic chemical space lies within 
the broad property envelope associated with potential bioactivity.   
 
So what do we mean by SAR in the context of this chapter? The concept of a series of close 
structural analogues with a range of quantitative bioactivity data that can form the basis for 
different types of predictive modelling is well understood but also continually developing [5]. 
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For in vitro data they need specific links between the entities of compounds, the protein 
bioentities  whose activities they modulate and the assays used to measure this.   These can be 
classified as (data supported) compound-to-assay-to-protein relationships [6].  Typically, a 
document “D“ describes a biochemical assay “A” with a quantitative result “R” (e.g. an 
IC50) for compound “C” (with an explicit structure)  defining it as an inhibitor of protein “P” 
(with a sequence and species-specific identifier).  Useful shorthand for these relationships is 
thus “D-A-R-C-P” (note the substitution of  “P” with target “T” can be  used to indicate a 
black-box mechanism of action such as a tumour cell or a tropical disease parasite).  This 
shorthand can be extended to describing a basic SAR series as a multiplexing of R and C, 
while a specificity cross-screen would be a multiplexing of  A, R and P.  Separate patent 
filings of SAR interest often cover closely related but distinct chemical series. These can be 
linked as a set  of “D”s that have A-R-P in common (since they were from the same 
institution  and reasonably  close in time)  but the different sets of “C” are varied.  
 
Medicinal chemists have traditionally manually extracted the key entities from patents and 
papers of interest and organised the relationships locally, thereby converting unstructured 
data from document text, chemical images, result tables and supplementary data into 
structured information (e.g. D-A-R-C-P in an Excel sheet).  It should also be pointed out that, 
beyond a sketching tool, access to patent office portals along with a basic familiarity of 
enzymology, receptor pharmacology,  and protein naming, a scientist can curate A-R-C-P 
sets from a patent on the day of publication within a few hours (i.e. in advance of any 
commercial extraction service). Notwithstanding, this presupposes that a) the indexing of the  
title and abstract allowed the specific retrieval of patents of interest and b) that these actually 
contained novel, useful and extractable SAR.  
 
While the ability to perform bespoke curation and annotation remains a core competence for 
medicinal chemists, they are increasingly likely to hand-off this activity for two main 
reasons.  The first is that commercial or public databases, as well as internal support from 
Information Scientists, can provide project teams with partial or complete D-A-R-C-P 
extractions from various sources.  For example, those with SciFinder access can collate the 
D-C records within days of publication but will still have to fill in A-R-C-P themselves (or 
from another resource).  The second reason is that drug discovery enterprises (academic or 
commercial) usually have local systems for collating, mining and modelling SAR originating 
from their own internal projects. These are now likely to include the use of Electronic 
Laboratory Notebooks (ELNs) for primary chemical structure registration and data capture. 
These are then extracted to populate in-house databases that increasingly also integrate  
external bioactivity data sources.  Pioneering examples of these include the AstraZeneca 
enterprise applications of Chemistry Connect [7] and SAR Connect [8]. What this means is 
that bespoke extractions are now expected to be format-compatible with internal systems and 
thus easily subsumed into them for intra-organisation sharing rather than languishing in local 
directories. 
 
An expanding range of curated compilations containing partial or complete D-A-R-C-(P or T) 
mappings are available as commercial products and deposited in public databases [9]. 
Depending on scale and update frequencies, these largely obviate the need for individuals to 
“roll their own” extractions.  However, a number of key points need to be made before 
reviewing some of these in the context of this chapter.  Firstly, the facility with which a 
medicinal chemist can extract a document is reflected in the resource curation model 
(commercial or academic) where professional biocurators are hired or contracted for scaling-
up essentially the same process. Secondly, full D-A-R-C-P extraction with useable specificity 
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has so far defied complete automation.  While text mining combined with Natural Langue 
Processing (NLP) is making progress towards this goal, challenges remain. The principle one 
is the need to semantically link structures, assay descriptions, result tables and protein 
identifiers extracted from different sections of a document. Experienced biocurators can 
cognitively discern these relationships in a matter of minutes but they increasingly use 
automated tools for triage and to improve their efficiency of capture.  Thirdly, while it 
actually violates the principle of patenting, some applicants in the medicinal chemistry 
domain deliberately introduce varying degrees of obfuscation into their documents (examples 
will be mentioned).  In practice this can not only make the elucidation of SAR relationships 
more difficult but in some cases impossible. 
 
The third point concerns patent coverage.  As testimony to the difficulty of managing a patent 
curation pipeline, compared to processing papers, even now relatively few resources can 
surface complete D-A-R-C-P sets from patents. Some commercial offerings may index a 
molecular mechanism of action (mmoa) but this is only a partial substitute for a standard 
protein identifier.  The  fourth point is that, in many cases, it is necessary to compare sources 
indexed for bioactivity as a surrogate for SAR per se. Consider, for example, a published 
report on an orphan (i.e. with no analogue structural neighbours) complex natural product 
that  potently inhibits malaria in a mouse model.  A record of this bioactivity is clearly 
valuable and worth finding but is not immediately useable for SAR exploration.  In contrast, 
extended data sets either where “T” uses  growth inhibition of the parasite in vitro with 100s 
of IC50 values for a designed synthetic library and/or recording Ki’s for the identical 
chemical series against one or even multiple  “P”s as purified Plasmodium enzyme targets.  
While filtering database entries between these different bioactivity levels can sometimes be 
done for papers, this is more difficult for patents.   
 
The content statistics of three databases in table 1 are partitioned into D-A-R-C-P metrics. 
The reason for selecting these in particular are not only that the relevant numbers are 
available from the teams concerned but also that, in combination, they sample the global  

















Table1.  Document, assay, result, compound  and protein target content counts for Excelra 
GOSTAR (commercial), BindingDB and ChEMBL22 as recorded in Sept 2016. Numbers for 
the latter were taken from the release notes except the protein target count was obtained from 
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the UniProt cross-reference.  Those from BindingDB were personally communicated by 








A R C P 
GOSTAR 110K 69K 17 mill 24 mill 7.3 mill 9212 
BindingDB 25K 1.2K 0.96 mill 1.3 mill 0.57 mill 6468 
ChEMBL 65K 1.2K 0.9 mill 5.6 mill 1.2 mil 6888 
 
There are caveats associated with table 1. These include that the individual data models give 
rise to differences in entity counts, redundancy reduction and relationship definitions. Note 
also that GOSTAR is a merge of a suite of databases.  Nonetheless, table 1 provides a useful 
quantitative overview.  We can briefly go through them in sequence.  As a commercial 
database, GOSTAR is the largest manually curated resource of chemical modulators of 
biological targets (mostly proteins) with associated activity data (mainly inhibition) extracted 
from papers and patents.  Notwithstanding the fact it cannot serve as an example of open 
patent mining,  it nonetheless provides  data-supported upper limits of extractable SAR from 
public documents. A 2013 analysis indicated the journal: patent compound split was 
approximately 1:2.7 with a document number split of 82K : 58K [10].  A recent update from 
Exelera (table 1) records current counts as 2.2 million structures from the literature, 5.1 
million from patents (i.e. a slight shift towards papers since 2013)  and an overlap of 0.19 
million (i.e. not much change).  Other relevant figures from the 2013 publication included 
that manual extraction yielded, on average, 12 compounds from a paper and 45 from a patent.   
 
The BindingDB figures are derived from an open database, not only in situ but also as a 
regular submitter to PubChem [11]. In addition, this resource supplies a set of D-A-R-C-P 
expert manual extractions of US patents  (reviewed later).  Since 2009 ChEMBL, also open 
and a PubChem submitter, is an open source of literature-extracted bioactivity and it also 
subsumes confirmatory PubChem BioAssays [12].  Full release statistics are available from 
which the headline numbers in table 1 were obtained.  Between BindingDB and ChEMBL 
there are similarities, differences and complementarity in terms of SAR content.  Firstly 
BindingDB subsumes protein-mapped ChEMBL content.  Consequently,  the former has 78% 
of compounds in common with the latter (although a proportion of these include identical 
structures collated by different routes). In addition, BindingDB has extracted 3K PubMed IDs 
not in ChEMBL. The average of 18.5   extracted compounds per paper for ChEMBL22 is 
slightly higher than for BindingDB at16, but below the current GOSTAR average of 20. 
Thus, these three independent numbers indicate a reasonably consistent yield of manual 
compound extraction from the medicinal chemistry literature along with the linked A-R-P 
data.  
 
So just how much total SAR is extractable from the journal corpus?  This question provides 
context for comparisons with patents but it is not easy to get a clean answer.  On balance, the 
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2.2 million compounds from papers extracted into GOSTAR indicate a plausible lower 
boundary, since the spread of journals and curation backfill time span is larger than 
ChEMBL. However, quantifying how much of this is useful for SAR modelling (e.g.  a series 
of analogues against the same protein as opposed to singletons with just one assay result) is 
less straightforward  (but the distribution could probably be discerned from GOSTAR 
internal statistics).  Upper boundaries remain uncertain but what we can record is that 92K 
PubMed entries are classified under the MeSH term “Chemistry, Pharmaceutical”  and 713K 
under “Chemistry”. While GOSTAR would not be expected to cover all bioactive chemical 
structures ever published, by their own selection criteria of SAR-density per-paper, they have 
probably captured well over the major part.  Given the PubMed figures above we can thus 
guestimate a conservative upper limit for ~3 million structures  as being within the wider 
frame of SAR interest.  Notwithstanding, as will be expanded on, ChEMBL constitutes the 
largest open resource of literature-extracted SAR against which patent sources and subsets 
can be intersected.   
 
Statistics of putative patent SAR 
 
As we have seen for the literature,  precise comparative statistics for document corpora entity 
content are difficult to come by.  Notwithstanding,  useful calibrations from automated 
extractions with a 2015 time point have been provided by SureChEMBL and the Minesoft 
Chemical Explorer (commercial).  The former declare 17 million compounds from 14 million 
patent documents while the latter claim 12 million from 10 million.  While the gap between 
these numbers and the 5.1 million selected for SAR content from the same corpus for 
GOSTAR is wide,  we can reconcile them to a certain extent via other methods of analysis 
and orthogonal queries to provide broadly plausible cuts.  The first filter we need to consider 
is patent family redundancy.  Using the World Intellectual Property Organization (WIPO)  
PATENTSCOPE database we can establish that 58 million national documents collapse to 3 
million international patent applications (PCTs or WO filings).  This indicates an average 
family size of 19 that, for the purposes of mining, can be considered as having the same 
chemistry content (despite post-examination claim scope changes). The other advantage of 
selecting WO is that they are generally the first family members to publically surface (for the 
record thought, these are technically only published applications since granting is done by the 
national authorities).   Their disadvantage for mining is that, compared to the XML format of 
USPTO applications from 2001 onwards, WOs have poorer text and image quality from 
suppliers of the electronic transformations. This degrades chemistry extraction, sometimes 
severely (this topic is addressed later).   
 
The second key filter is to identify relevant chemical content.  As a first step towards the 
latter we can use the Intentional Patent Classification (IPC, see website listing). This is a 
hierarchical system where C for “chemistry” accounts for 20% of the WO. However, the 
combination of C07 for “organic compounds”  and A61K “preparations for medical 
purposes”, while not 100%  specific, is highly selective for small molecule drug discovery, 
medicinal chemistry and therefore potential SAR content (n.b. not all relevant national filings  
proceed to a PCT and some not captured in this intersect may be using submission tricks to 
“hide”). The individual numbers, via PATENTSCOPE, are 217K and 235K respectively with 
a C07/A61K intersect of 85K (for comparison A01N “herbicides and insecticides” has 29K 
WO with 7.4K of these intersecting with C07).  The corresponding C07/A61K count  for 
EPO publications is 371K which drops to 233K for USPTO.  Despite the uncertainties on 
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absolute document redundancy (e.g. further collapsing by Kind codes) we can make a 
plausible estimate that the medicinal chemistry relevant patent subset could be in the range of 
100K to 200K.  We can then use the average count of 257 unique IUPAC structures per 
patent from recent exhaustive extraction exercise to make a total chemistry estimate for the 
C07/A61K set of just over 25 million.     
 
Compared to document counts in the high millions often highlighted by patent indexing and 
extraction resources, these numbers for the medicinal chemistry intersect seems lower than 
might be expected.   However, it is comparable to the GOSTAR extracted patent count of ~ 
70K in table 1 which is SAR selective.  The yearly WO published output corresponding to 
C07/A61K can be plotted (figure 1). The result  clearly mirrors the published rise and fall in 
the concomitant GOSTAR chemistry extraction indication  the amount of patent SAR has 




Figure 1.  A plot of the per-year WO patent counts for the intersect between the IPC codes 
C07 and A61K. The September 2016 total was 85K.  
 
While commercial operations are triaging this output, it is difficult to get open statistics that 
could support SAR estimates.  For example, the family redundancy between the WO, USPTO 
and EPO is unclear (even though some measure might be obtainable from the INPADOC 
system).  Note it is possible to select  granted vs non granted applications in USPTO as a 
nominal quality filter and redundancy reduction. However, not only does the time lag for 
examination run into years but also granting is by no means a guarantee of scientifically 
useful content.  What we can attempt is to empirically divide C07/A61K into data-centric 
utility groups (i.e. not based on IP considerations) with respect to putative SAR content.  
These can be outlined as follows; 
 
1. An extended chemical series, including synthesis and analytical details with novel 
composition of matter, described as directed towards a specific target and a set of 
diseases, possibly including assay descriptions.  However, beyond a general 
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statements, such as “found to be active”, no data can be assigned to individual 
structures. 
 
2. As above but with a proportion of the examples having aligned bioactivity data, 
although much less than the number of example structures and/or heavily gapped. 
 
3. Assignments of activity to each exemplified structure but only as ranged values. This 
can be typically in the form “between 10 and 100nM or 100 to 500 nM” or using a 
binning system of one to five stars, ABCDE or suchlike.  
 
4. The document includes a complete set of discrete assay results, typically IC50 or Ki, 
displayed in a data table with anywhere between 5 and 500 rows. These can be 
aligned with the structures (novel at filing time) and their synthetic descriptions. By 
definition, this constitutes the most useful SAR patent (particularly if cross-screening 
data from two or more parologous proteins are included) but note the results may be 
generated with assay formats that do not use purified proteins (i.e. “T” not “P” )  
 
5. Documents along the lines of 3 of 4, ostensibly including an extensive set of results, 
but where the degree of obfuscation in the description or layout (e.g. activity and 
example numbering not being in register) is high enough to preclude unequivocal 
SAR mapping. 
 
6. A category that encompasses what we can term secondary filings in the sense that 
structures have been filed previously, are not novel and few in number.  These can 
include crystallisation or synthetic route descriptions by the erstwhile originators of 
the lead compounds as well as generic manufacturers jockeying for inventive claims 
on clinical candidates.    
 
7. Outside the above there are many filings that defy any simple classification. They  are 
still assigned the two codes we deem useful but for various reasons difficult to discern 
SAR. Perhaps the most interesting are data supported authentic new uses for 
previously claimed structures (i.e. repurposing). Others may cover mixture 
combinations, often with huge permutated listings. Some include various types of 
virtual enumeration where potential activities for structures are claimed that have 
neither been made nor tested. 
 
 
The informal categories above can be assigned by detailed inspection of patent documents. 
However, they expose the problem that there are no statistics as to how these are partitioned 
at scale. Consequently, there are no reliable methods of automated SAR detection.  While 
2,3, and 4 are of primary interest,  some of the other categories could be useful. For example, 
in category 1 there are fillings by drug discovery teams with an established reputation but 
whose project leaders or company management take the strategic decision to file a chemical 
series without disclosing any activity data. Notwithstanding, these are logically expected to 
include actives (i.e.  a series with cryptic SAR) to justify  the IP investment  in the first place. 
They can certainly be used for modelling (e.g. building a pharmacophore) and some 




Identifying specific patents 
 
Retrieval of patents with a view to significantly enriching for categories 2,3, and 4 above,  is 
a major subject that cannot be covered in depth here. However, examples will naturally 
emerge as we explore queries in different resources.  In the interim, we can outline the 
general challenges but even before this we need to clarify operational imperatives in the  
context of this chapter.  In searching databases that include patent-extracted chemistry in the 
context of IP due-diligence the consequences of false-negatives (e.g. overlooking relevant 
prior art) for any drug discovery organisation can be dire in terms of economic cost and 
erosion of competitive position.  However, the assumption is made here that if an individual 
happened to miss some patent SAR that was retrospectively found to be relevant  they would 
not be held to account too severely (although the same oversight from patent attorneys or 
Information Sciences teams might not be seen in such an equable light).  Another real-world 
consideration is that researches are likely to be more focused on the SAR of the present rather 
than the past. This is especially so since the latter is well covered by review articles (e.g. the 
journal ” Expert Opinion on Therapeutic Patents”).  This means researches are unlikely to 
want to pull back SAR from decades ago and are thus more likely to filter for more recent 
time spans (where the chemotypes, potencies and properties should, at least implicitly,  be 
improving) . Thus, in regard to the strategic dilemma of specificity vs recall,  examples used 
here will be high-specificity  queries and recent time scales in order to reduce time spent 
triaging false-positives for rejection,  rather than being overly concerned about missing false-
negatives or older filings.   
 
As we know patents can be identified by their metadata such as inventor names, affiliations 
and patent classification codes (even though these can have noisy indexing). Filtering or 
ranking by publication date is of course useful but can be confounded by families, Kind codes 
and priority equivalents which can surface identical documents across time spans of five 
years or more.  However, examples below will concentrate on target-centric searching that, 
while certainly prone to false-negatives, has an acceptable specificity.  In addition, target 
searching is the most common first-pass for literature searching so that grappling with protein 
naming issues becomes more familiar.    
Chemistry extraction 
 
As mentioned, manual curation of SAR from a patent is intuitively obvious to medicinal 
chemists, many of whom have engaged in generating the data that goes into them and may 
even have had a hand in drafting applications.  However, most sources that have pursued the 
large-scale manual extraction of chemical structures from patents (with or without A-R-C-P 
mapping) have been commercial. This means that technical details of their selection and 
triage are not usually disclosed.  However, being proprietary about exactly how databases are 
populated always leaves users with uncertainties.  In particular, it is important to know 
curation strategies and chemistry business rules that might directly affect how easily and how 




 How are ambiguous partial stereo centres handled? 
 Is the parent added as an extra structure where the document specifies a salt? 
 Are obvious applicant-originated  chemical errors fixed?  
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 What activity units do they normalise to? 
 Which software do they use to output their sketched structures?  
 What primary standardised chemical representations are captured from this output? 
 Are activity figures rounded down? 
 Do they number structures corresponding to their example numbers in the document 
(i.e. so the extracted structure can be unequivocally matched to the activity values 
even if it is exemplified multiple times)? 
 Do they have capping rules for very large SAR tables? 
 Are all examples extracted or only key structures selected by the curators? 
 Do they add the structures of known drugs or clinical compounds even though may 
these may only be specified by a semantic name?  
 
Users who commit a lot of searching time to any particular curated resource may have to 
work these rules out “backwards” during the course of their analyses. They can also compare 
between sources (e.g. for the same patent number) but this does become time consuming.  
 
By definition, the manual throughput of chemistry and other entity extractions (e.g. A-R-C-P) 
from documents factors linearly with the cost of biocurator time.   For this reason, the 
technology with the greatest impact on open chemistry extraction in recent years (and 
provision of structures  that can potentially be SAR-mapped) has been automated Chemical 
Named Entity Recognition (CNER). This scales approximately according to computing 
power and algorithmic efficiency.   In essence, electronically formatted documents go into a 
pipeline and structures come out.  As well as indexing the chemistry, outputs may be tagged 
with metadata,  such as whether they were derived from text and/or images, recognised in the 
title, abstract, description or claim sections.  In practice CNER extends beyond just text-to-
structure (n2s) to encompass automated image-to-structure (i2s) as well as manually draw 
ChemDraw files then automatically converted to molfiles structures.  These are generated by 
the USPTO Complex Work Units (CWU) process as part of their pipeline for complete 
electronic processing of patent applications.  While researchers mining patents do not need to 
keep abreast of the details of CNER technology,  it is important to understand the associated 
strength and weaknesses, particularly from the point of view of exploiting  resources derived 
from it.  A useful schematic describing SureChEMBL is shown in fig.3 (interrogation  of this 







Figure 3. A diagram of the SureChEMBL CNER pipeline (adapted from [13]).  
 
The basic operations shown in fig. 3 are n2s  and i2s.  The first is via conversion of IUPAC 
systematic names as a text strings but this also encompasses what we can call semantic n2s 
where names such as “atorvastatin” are converted into explicit structures via a look-up 
dictionary.   The second is via image processing for i2s that also includes the CWU-derived 
molfiles. We can now move on to see how the interplay between manual inspection and 
automated extraction can be exploited for SAR retrieval.    
Patent SAR retrieval from BindingDB 
 
Before assessing CNER resources it is instructive to explore one of the few open resources 
that include manual patent extraction of complete D-A-R-C-P sets.   As of Sept 2016 
BindingDB had curated 1229 US Patents with target-directed small molecule binding data.  
While a relatively small number (now mirrored in ChEMBL22) it has the advantage of being 
produced by the expert triage of recent USPTO  publications  selected via the inclusion of 
Kd, IC50, Ki or EC50 in the abstract.  The triage also selects for CWU molfiles that  provide 
complete sets of example structures, thereby enabling the expert manual curation to focus on 
target identification and activity mapping.  There is a pointer to this section from the front 
page or lower down on the left hand facets under citation sources. There is also an Advanced 
Search tools option for focused searches within just the patent data (or other sets).  The top-






Figure 3.  Entries from the BindingDB patent extraction page. The numbers under the “Data” 
column are measurement counts.  Each of these has a PubChem CID derived either from a 
BindingDB submission (as an SID) or it matches a pre-existing CID from another source.  
The majority are unique within this patent set but there is some multiplexing for dual values 
(e.g. Ki and EC50) or multiple target cross-screens.   
 
These BindingDB true-positives (i.e. most being from category 4 above) serves not only as a 
useful introduction the principles of SAR mining but also to benchmark other resources.  A 
disadvantage is that, as USPTO publications, these can lag some time behind the surfacing of 
WOs.  For example the most recent in the list, US9199947 published on Dec 1, 2015, was 
first published as WO2014154727 on Feb 2
nd
, 2014. However, since it is the availably of the 
CWU structures that make this pipeline possible in the first place, WO documents cannot be 
used.  As a first look at the set, we can plot the number of compounds per document to 
display the SAR distribution (fig. 3).  
 
 
Figure 4.  1218 curated patent documents from BindingDB  (horizontal axis) ranked by 
number of compounds x activities (the 14 with over 800 were truncated  out of the vertical 
axis range). Over 80%  have 20 or more SAR records and nearly 30% include at least 100. 
(n.b. the average measurement record per-patent of 98 is comparable to the GOSTAR non-




The most common first-pass strategy is to search by target name. However, as we can see in 
the list,   the use of unambiguous protein names by applicants is patchy and titles such as 
“Chemical compounds” (US9156831) immediately present the false-negative problem. 
Notwithstanding,  in this case cell proliferative disorders is mentioned in the  abstract, the 
description goes on to specify PI3K-α and PI3K-δ and BindingDB curation has resolved the 
activities against PIK3CA, P42336.   We can move on to the question “how many BACE1 
patents can we find in this list?”.  Note that the BindingDB has already resolved the targets 
during their triage  (i.e. there are 8030 records linked to BACE1, mostly from papers) but we 
in this case we can use the text query to illustrate general principles of patent retrieval.   
 
Table 2.  Entries from BindingDB patents that can be retrieved by related target names.  The 
first 14 rows are matches for  “BACE”, ranked by compound count. The last two rows are 
matches to “memapsin” and “beta secretase”.  
 
 
Patent Data Patent Title Organization Deposition 
US9181236 290 2-spiro-substituted 
iminothiazines and their mono-
and dioxides as bace 
inhibitors, compositions and 
their use 
Merck Sharp & Dohme 
Corp. 
08/29/16 
US8865911 180 Compounds and their use as 
BACE inhibitors 
Astrazeneca AB 04/06/2015 





US8748418 53 1,4-oxazepines as BACE1 




US8541427 45 Phenyl-substituted 2-imino-3-
methyl pyrrolo pyrimidinone 
compounds as BACE-1 
inhibitors, compositions, and 
their use 
Merck, Sharp & Dohme, 
Corp. 
11/26/13 
US9000182 41 2H-imidazol-4-amine 
compounds and their use as 
BACE inhibitors 
AstraZeneca AB 10/19/15 
US9145426 38 Pyrrolidine-fused thiadiazine 
dioxide compounds as BACE 
inhibitors, compositions, and 
their use 




1′,2″-imidazol compounds and 
their use as BACE inhibitors 
AstraZeneca AB 10/19/15 
US9067924 24 1,4 thiazepines/sulfones as 






1′,2″-imidazol compounds and 
their use as BACE inhibitors 
Astrazeneca AB 10/19/15 
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US8940748 21 Iminothiadiazine dioxide 
compounds as BACE 
inhibitors, compositions, and 
their use 
Merck Sharp & Dohme 
Corp. 
06/16/15 
US9000185 18 Cycloalkyl ether compounds 
and their use as BACE 
inhibitors 
AstraZeneca AB 10/19/15 
US8703785 9 2-aminopyrimidin-4-one and 
2-aminopyridine derivatives 
both having BACE1-inhibiting 
activity 
Shionogi & Co., Ltd. 10/14/14 
US9029367 5 BACE inhibitors Eli Lilly and Company 11/16/15 
Synonym matches 
US9096541 28 Inhibition of memapsin 1 







US8637504 37 Sulfur-containing heterocyclic 
derivative having beta 
secretase inhibitory activity 
Shionogi & Co., Ltd. 08/22/14 
 
The results in table 2 indicate some of the obstacles to target name resolution.  An initial test 
with “BACE1” gave only four matches. A stemming variation  “BACE” gave 17 matches but 
only to the 14 records in table 2.  It happens that BACE is both a synonym for BACE1 and a 
common stem for the paralogous pair of BACE1 and BACE2.  Importantly for SAR aspects, 
these two are both targets for Alzheimer’s Disease and type 2 diabetes, respectively [4] and 
are also sometimes used in reciprocal cross-screening (thus expanding the SAR).   Hence 
“BACE” not only conveniently picks up all the BACE1 single-target filings but also 
US8754075 and US8748418 as “and/or” double-target filings [14] .  We also find 
US8541427 that uses an incorrectly hyphenated BACE-1 as symbol.  However, “BACE” 
misses two false-negatives that, from testing the common synonyms,  we can retrieve with 
“beta secretase” and “memapsin 1”.  The latter is a synonym for BACE2 which makes 
US9096541 nominally the only BACE2 single-target filing in this set, but the data also 
include BACE1 cross-screening results.  With the proviso of needing a registration log-in, 
BindingDB facilitates the full download of SAR sets.  An example is shown in  table 3.  
 
Table 3.  Selected structure-to-activity  records from US8748418. The complete table of 53 
rows and a detailed set of columns was edited down to just the columns and rows below and 






Target Name Assigned by 





123867 US8748418, 12 Beta-secretase 2 (BACE2) 5 68307545 
123862 US8748418, 6 Beta-secretase 2 (BACE2) 11 60194542 
123857 US8748418, 1 Beta-secretase 2 (BACE2) 24 66547140 
123869 US8748418, 14 Beta-secretase 2 (BACE2) 28 66547488 
123864 US8748418, 8 Beta-secretase 2 (BACE2) 30 66547317 
123862 US8748418, 6 Beta-secretase 1 30 60194542 
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123858 US8748418, 2 Beta-secretase 2 (BACE2) 35 66547141 
123858 US8748418, 2 Beta-secretase 1 40 66547141 
123870 US8748418, 15 Beta-secretase 1 40 66547492 
123870 US8748418, 15 Beta-secretase 2 (BACE2) 58 66547492 
123857 US8748418, 1 Beta-secretase 1 70 66547140 
 
Importantly, these can be related to their positions in the patent document and detailed 






Figure 5.  Original SAR Data from US8748418 aligned with the example images and IC50 
data from page 32 of the PDF. Example 1 = BindingDB 123857=US8748418, 1 = CID 




Figure 6.  The database entry  for BindingDB 123857.  The  IC50 is specified along with with 
a citation  for the assay. In addition  many outlinks are presented such as the protein target in 
UniProt,  the patent document (in Google and the USPTO portal)  and the structure in 




The utility of this “pre-cooked” SAR is clear.  However, if significant downstream effort is 
going to be invested in the data set (e.g. modelling and/or synthesis) it is prudent to cross 
check extractions (from any source in fact) against the original document.  In this case 
US8748418 reveals 28 examples in the patent table 1, thus indicating the 53 BindingDB 
records have both BACE1 and BACE2 assay results as the SAR set.  We can now compare 
this with a CNER source.  
Patent chemistry in SureChEMBL  
 
In a relatively short space of time SureChEMBL [13] has become the major public source of 
chemistry from patents since it had accumulated 17.25 million structures by the end of 
August 2016 (as indexed in UniChem [15]) .  This not only offers advantages of scale but 
also speed because in situ (i.e. without the lag time associate with feeding-on to other 
databases such as UniChem or PubChem) chemistry from an individual patent document is 
downloadable within days of publication. The main limitation is that the primary relationship 
capture is only D-C. This means that users have to connect A-R-P data for the collation of 
SAR.  As an example we can compare what SureChEMBL extracted from US8748418 where 
we have just located the SAR series manually extracted by BindingDB. One of the many 




Figure 7.  SureChEMBL queries  related to the BindingDB 123857 structure.  The upper 
panel shows the result of an exact-match  structure search. This gives 9 intra-document 
matches, one of which an image-conversion (corresponding to figure 5) with the IC50 values 
in the lower left.  The lower panel shows the inter-document matches across four family 




We can download a table of the entire (i.e. unfiltered and redundant counts) chemistry 
records that SureChEMBL has extracted from US8748418 by a combination of n2s, i2s and 
CWU molfiles.  This gives 876 rows.   Extending this to all the family members increases to 
1581.  We thus see the main advantage of CNER in presenting what is probably close to total 
chemistry extraction. The important proviso is that achieving this is dependent on pre-
processed patent text and image quality.  The problem is that a priori from the download we 
cannot directly establish which of these have any SAR (i.e. could correspond to the 28 
examples that BindingDB has already identified). Notwithstanding, this can be done 
manually within SureChEMBL by scrolling though the automatic mark-up of Table 1 in the 
document (i.e. each of the 28 images in this case).  Insights into CNER output can be 
discerned in table 3.  
 
Table 3.  The 11 records in the SureChEMBL download  for SCHEMBL12273617  




The key points are ; 
 
 Multiple extractions of the same structure have been made from the four family 
members 
 The n2s and i2s are concordant (i.e. alternative extractions produce the same ID) 
 For the US application (A1) and grant (B2) the intra-document count was eight, split 
between two different IUPACs and one image 
 The EP and WO missed one conversion (probably an image) 
 The “corpus count” across all of SureChEMBL  provides  a reassuring inter-document 
consensus for this particular structure  
 Manual inspection of the documents confirms the statistics of the data download in 
that Roche have exemplified their active series eight times 
 This seems unusually high but we have no overall statistics to test this 
 
The useful aspect of this example is that, using foreknowledge of the BindingDB extraction 
(albeit done at a later date) we can explore multiple ways of discerning the correct SAR 






   
Figure 8.  A plot of the corpus count (the vertical axis, truncated at 100 occurrences) for the 
non-redundant SureChEMBL chemistry download for US8748418.    
 
The corpus count distribution of US8748418 shows the pros and cons of CNER pipelines in 
general. The problem is that most of the processing effort goes in to the continual re-
extraction of frequently specified compounds (e.g. methanol occurs 7.2 million times across 
the SureChEMBL corpus and the name match finds 0.9 million documents).  This is not to 
say that the statistics of common chemistry do not have utility for certain applications (e.g. 
surveying synthetic trends [16] ) but these extractions can swamp out the bioactives.  
However, the leftmost section of fig.8 indicates that lower corpus counts probably represent 
a) novel structures and b) encompass the SAR series. However, while from table 3 we might 
expect 17 to be an SAR-specific cut-off, it turns out that the occurrences from 10 to 20 form a 
continuum of approximately 70 structures rather than a clean set   However, a key feature of 






Figure 9.  SureChEMBL chemistry export filters for individual patent documents or whole 
family extractions. Note the default Mw window is 300-700 but this was narrowed down 
since we have established that SCHEMBL12273617 (CID 66547140) has a Mw of 407.  
 
Toggling these settings can be complemented by further post-download filtering (e.g.  
removing SureChEMBL ID duplicates and selecting occurrence ranges in the description 
section)  to enrich for an SAR series. However, even with these options we are still left with 
96 structures (i.e. within which should be the 28 we would like to identify).  The caveat with 
Mw filtering is that it may encompass larger intermediates that are still novel structures but 
for which no bioactivity was reported.  Corpus counting has the caveat that low frequencies 
of one or two (i.e. well below the document family count) may be chemically plausible 
structures but could represent artefactual extractions.   
 
Regardless of the challenges of isolating an explicit SAR-linkable set,  the facility to 
download patent chemistry extractions in SureChEMBL is powerful.  There are however 
complementary ways to approach the isolation problem that can be revealed by manual 
inspection of context within the document. We have already seen this with the 
straightforward identification of the image structures and IC50 data in table 1 of the patent.  
A second useful option is to simply browse the SureChEMBL mark-up and spot sets of 
structures that look as though they could be matched to activity tables.  An example of this is 







Figure 10.  List of IUPAC names from page 11 of the US8748418 PDF. The unbroken blue 
highlighting means that SureChEMBL has made a successful IPUAC conversion to a 
structure in each of the 27 cases. They would thus be included in the download. In addition 
each one has a link to information about the structure (as shown in fig. 7). 
 
The ability to identify such large sections in patent mark-up (either as a blue highlighted 
IUPAC strings and/or a green border around the images) is useful for both for assessing the 
quality  of extraction and delineating examples.  In this case the series is not numbered so we 
cannot reliably link the structures to the data table rows in any automated way. However, 
example assignments (e.g. Example 1,2,3, etc.) can be found further down in the synthesis 
descriptions and thus manually collated via the compound displays.  This example thus shows 
both the generic problem for SAR-digging and the solution via manual collation. Additional 




Target searching in SureChEMBL 
 
Having looked at target-specific retrieval  in BindingDB we can compare this to searching the 
much larger patent set in SureChEMBL.  It is also important to understand the major 
difference between these resources.  The latter has indexed the full content of the docments 
whereas BindingDB only indexes what has been expert selected (but this includes the target 
name, UniProt ID, quantitative affinity values, etc.).   We can look at a configured query in 




Figure 11.  A BACE1target query  in the SureChEMBL interface showing four filters, query 
string (main box)  location (doc sections toggle)   patent classification code (lower panel) and 
WO as patent authority (right hand panel) 
 
The filters in fig. 11 were selected primarily for specificity rather than recall (i.e. to give a 
good yield of true positives).  The first filter is the HGNC gene symbol and two common 
protein synonyms as described for the BindingDB search in table 2.  We have used C07D as 
the second select but we can skip A61K in this case since we are already selecting a 
biological target. The third select is to search the only the title and abstract rather than the 
entire text that can could include false-positives as incidental mentions of the target.  The 






Figure 12.  Results for a search in SureChEMBL with the selections specified in fig.11. Just 
the top-10 are shown from a total of 369 WO document hits.  
 
Useful circumstantial information on SAR-likelihood can be gleaned from inspecting the 
retrieved title list even before opening up the individual documents (although less obvious 
aspects need some experience to be discerned).  For example, we can see all three synonyms 
have been used by applicants and the patent titles appear to be true positives (n.b. we did not 
need this for the BindingDB search since they were pre-selected ).  It is also clear that we 
might  have used “inhibitor” as another filter but this could have an associated false-negative 
risk.  As we could already see from BindingDB, this larger result set confirms that BACE1 is 
a popular target since no less than five pharmaceutical companies are slugging it out even in 
just these 2016 publications.  Another clue we can pick up on is that Merck have a secondary 
filing as “crystalline forms”  which, by implication,  should connect the structure back to an 
earlier novel active series that might include SAR.  As additional context, we can also 
establish that both Merck and AstraZeneca have candidate BACE1 inhibitors still in clinical 
trials with Roche having had  RG7129 in Phase 1 but terminated. We can thus infer that these 
recent filings from these three companies could include SAR from back-up and/or follow-on 
series for each of those clinical candidates. Roche have assigned identical titles to two 
different WO numbers that, by definition, should therefore include different chemistry claims 









Having assessed the titles we can zero in on some of these documents to illustrate particular 
points.  The trio of titles from Lundbeck seem worth investigating  because, as mentioned in 
the introduction,  they could be a set of “D”s that have A-R-P in common and where “C” is 
an extended series.  This turns out to be the case, with the three filings including individual 
Ki data tables for 41, 14 and 19 structures.   We can pick out the following aspects from this 
set:  
 
 They present a complex set of patent families but further down in the hit list we can 
find a yet a forth SAR set of 48 structures with Ki results in WO2015124576 from a 
2-amino-3, 5, 5-trifluoro-3, 4, 5, 6-tetrahydropyridine series.  
 
 SureChEMBL did a good job on all four sets. Notably, two had already appeared as 
US publications (e.g. WO2015124576 as US9353084 and WO2016075063 as 
US9346797) which, as expected, gave better extraction results.   
 
 It turns out that WO2016075064 has unusual content.  Firstly,  there is a 3D crystal 
structure image of what was extracted as CID 121334268 . This provides a 
configuration for the series but had no reported activity data.  Secondly, examples 16 
and 18 were deuterated.  This confounds a standard CNER pipeline both because the 
i2s did not recognise “D-“ and the text OCR missed the  “-d3” (although the n2s 
would have converted it within an IUPAC string) . To complete the SAR set  a 
chemical sketcher could be used to input the two deuterated compounds (n.b. it may 
also happen that when this filing eventually surfaces at the USPTO the deuterated 
images will be linked to the document as molfiles via CWU processing).  
 
Tools for stand-alone extraction  
 
There are several options to collate SAR from US9346797 but this needs the example 
numbers to be matched to the data table on page 30 of the PDF.  Analogous to the 
conversions of the example list indicated in figure 10, the sets are visible in SureChEMBL 
but in this case the applicants have usefully numbered them to match the Ki values that the 
document processing has extracted as text.   While the SureChEMBL document chemistry 
export (at default filter settings) produced 114 rows that reduced to 55 unique structures, 
there was no easy way to isolate the 14 examples in the correct sequence.  However, we can 
exploit the ordering by converting them extrinsically using a stand-alone operation. The 
resource of choice here was the open ChemAxon chemicalize resource that allows users to 
run n2s on text from a variety of sources an input formats [17]. In this case an external web 
page was made for batch conversion with just the 14 IUPACs pasted across from the 
SureChEMBL text (n.b. this may seem redundant since they have already been converted to 
structures but note that isolating just the selected strings and maintaining the order is 











Figure 13.  The SAR series from US9346797 extracted using chemicalize.   Page 36 from the 
patent PDF specifying the structure is shown on the left. On the right are the chemicalize 
webpage conversions of the same numbered examples pasted over in the same order.  The 
IUPAC for example three is highlighted in orange which also displays the ChemAxon 
structure rendering on mouse-over.  
 
One of the features of chemicalize is that we can download an SD file from the webpage 
extractions in which the extraction order is maintained.  This can then be easily transformed 
using commercial packages or open resources such as OpenBabel [18]. Thus,  a combination 
of using SureChEMBL, chemicalize.org together with some manual collation and cross-
checking against the original PDFs to tie things together, we can generate a complete Ki SAR 
set for the 96 tetrahydropyridines.   Cases where SAR extraction presents more of challenge 
include the most recent in the figure 12 set , WO2016096979  from the  Jansen team in Spain.   
We can quickly find SAR in the form of two different assays already log transformed to 
pIC50s  cross-referenced against 33 compound numbers.  Here again the OCR does a 
sufficiently good job on the data table to be copied over to Excel with the rows staying in 
register and the greater than signs as we can see in figure 14 (even though the out-of-range 







Figure 14.  Three versions of the SAR table from WO2016096979. On the left is the original 
from page 64 of the PDF. In the centre is the corresponding section of the SureChEMBL 
mark-up. The right hand panel is an Excel paste-across of the centre section.   
 
However, the failure of many of the ChEMBL chemistry conversions indicated that, 
compared to what we have looked at so far,  it would not be straightforward to resolve 




Figure 15.  Chemistry for one example  in WO2016096979.  The compounds associated with 
Example B7 in the original PDF are shown on the left with the corresponding SureChEMBL 
section on the left.  Note the “Highlight additional recognised chemical terms” option was 
toggled on. The consequent appearance of the grey highlighting indicates where the n2s 
recognised a potential name (i.e. an IUPAC-like text string) but could not generate a structure 
(in which case the highlighting would have been blue).    
 
Inspection of the SureChEMBL output establishes that text quality had confounded the n2s 
algorithms.  The extraction problems in this document were compounded by the i2s 
introducing an artefactual iodine from converting the B7 image (unfortunately now 
permanently enshrined in CID 121433102).  One option would be wait for the US patent to 
surface with improved conversions.  However, we can see the original document contains the 
necessary information we need for SAR collation  but arranged in a somewhat complex way 
(e.g. example numbers are nested  intermediates for the compound numbers that are also 
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depicted in Markush tables).  Below is the SureChEMBL text associate with compound 19 
from fig. 15, where the obvious OCR errors are marked in red. 
 
N-r3-r(26',3i?)-5-amino-2-methyl-3-(trifluoromethyl)-3,4- dihvdropyrrol-2-yl1-4-fluoro-
phenyl1-5-chloro-pyridine-2-carboxamide.   
 
The tool we can use for stand-alone n2s is the Open Parser for Systematic IUPAC 
Nomenclature (OPSIN) [19] . While the web interface is only suitable for small numbers of 
conversions it has the advantage over Chemicalize of presenting error notifications and also 
allowing trial-and-error iterative editing of the input text.  By this means we can correct 





Figure 16.  Conversion of compound 19 from WO2016096979 using the OPSIN interface. 
The input (after editing corrections)  was N-[3-(2S,3R) [5-amino-2-methyl-3-
(trifluoromethyl)-3,4-dihydropyrrol-2-yl]-4-fluorophenyl]-5-chloropyridine-2-carboxamide.    
 
With some editing it now becomes possible to generate compound 15 as the “flat” 
chloropicolinoamide as well as specifying the resolved enantiomers of the carboxamide for 
19 and 20 by editing the IUPAC S/R prefixes.   To demonstrate another useful open tool set 
we can corroborate the i2s from the left hand side of figure 15  by using the Optical Structure 






   
Figure 17.  The  OSRA result for conversion of the downloaded image from fig.15.  The 




This WO2016096979 example shows the synergies of working between the original 
document, the SureChEMBL output with addition of the OPSIN and OSRA tools 
(chemcalize could also have utility here depending on individual preferences).  While it has 
to said that collating the complete SAR set from these 33 examples,  including the 
enantiomeric splits, would require some effort, the combined approach brings  many other 
such “difficult”  documents within practical reach of extractability.   It is important to note 
that, due to partial failure of the SureChEMBL conversions, many of these examples will not 
be in PubChem.  
Selecting for SAR 
 
A particular advantage of full text indexing in resources such as SureChEMBL is that, 
regardless of the expected specificity issues, simple searches such as “IC50” or “inhibitor” 
actually work (108,115 and 650,147 documents respectively,  with an AND union of 56,870).  









Figure 18.  The most recent matches  (from 138  in total ) SureChEMBL search with for 
matches to BACE1 and IC50 or Ki and C07 within WO documents 
 
We can see that the fig. 18 has matches in common with fig 12 and spot what seems a likely 
consecutive series  from Roche as WO2016150785 and four months earlier WO2016071211 
both titled “BACE1 inhibitors”.  Inspection reveals these to be true-positives with 
WO2016150785 having  seven intra-document IC50 matches including  “Table 1 : IC50 
values of selected examples”.   While there are only four intra-document matches in 
WO2016071211 and the result table is not numbered,  we can pick out both tables. This 
Roche appear to be true-positives for the IC50 trawl on the one hand, but may present 
borderline SAR-value on the other.  The first issue is data sparcity (compared with what we 
have seen so far) since in WO2016071211 only 12 of the 25 IC50 examples have data and in 
WO2016150785 its 38 from 44.  We can also see signs of probable deliberate obfuscation in 
the use of confusing nested numbering systems.  However, a more serious issue we can 
immediately spot is difficulties for chemistry extraction because the poor OCR has 
confounded most of the n2s (including  extensive introduction of the notorious 1-to-l 
conversion errors).  While the i2s has fared better in at least getting structures out,  the 
multiple conversions from small images in the tables present a confusing picture.   We can 






Figure 19.  The first three examples from Table 1 in WO2016071211 are in the top panel. 
The SureChEMBL rendering is shown, with the green boarder signifying an intra-document 
search match. The image conversions from this section of the table have spawned the three 
structures in the lower panel (but not necessarily in order). From left to right in the panel 
these are in PubChem as CID 121329828, CID 121329766 and CID 121329765.   
 
We can follow these structures “back round” in the sense of mapping them back to their 
locations in the document (via PubChem or inside SureChEMBL).  However, we see a 
peculiar pattern of stereo enumerations and “flat” structures that are matching multiple 
different example numbers (e.g. two and three are identical).  The minimum parsimonious 
assumption is that these multiple mappings could be due to errors in the document.  At the 
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end of the day this example can be seen as a cautionary tale.  Thus, WO2016071211 would 
seem unreliable for SAR modelling and not worth spending time with any tools to try to sort 
things out.  However, thanks to the SureChEMBL “efforts” we can at least see the series 
chemotype.  
 
Connecting between patents and papers via PubChem 
 
Explorations of patent SAR naturally generate a range of questions with respect to the 
literature.  The two basic ones are (Q1)  “have any of the bioactive structures in this patent 
appeared in papers?  The converse question (Q2)  is “have any of the bioactive structures in 
this paper (in particular the lead compound)  appeared within a (possibly larger)  SAR series 
in a patent ?   These questions thus look forwards or backwards in time and can both be 
important. There are technically different ways to approach the questions and with different 
search stringencies (e.g. an exact match, a connectivity match,  a similarity match  or multiple 
matches across a series).  Before looking at some examples it is important to understand the 
time relationship of what surfaces where when, how much and who cross-points to whom.  
Starting with patent chemistry in PubChem first we can establish that it contains 16.3 million 
substances from SureChEMBL up to the 6
th
 of August. We can also check that in situ the 
latest extractions were only three days behind the publication date. While the lag-time in 
PubChem is thus about a month,   this is more than acceptable for a free resource.  There are 
four other sources of patent chemistry in PubChem that each have more than a million 
structures (see table 1 in [2] for a 2015 snapshot) but three of these are static and are not 
likely to update.  Selecting SureChEMBL, IBM, SCRIPDB and NextMoveSoftware (all 
CNER sources) adds up to 19.7 million compounds with 82% coming from SureChEMBL.     
PubChem is extensively connected to the literature via different types of CID-to-PubMed 
connectivity  [20] one of  which includes ChEMBL via the PubChem BioAssay database.  
However there is an associated lag time for when  PubMed IDs (PMIDs) are connected to 
CIDs,  because ChEMBL release times are well over six months.  Nonetheless, there are 
multiple ways to answer Q1 and Q2.  One of these is by following the reciprocal cross-
pointers between PubChem, SureChEMBL, ChEMBL and UniChem. This means for any 
individual structure we can follow inter-database and paper-patent connectivity without doing 
any searches at all (this was already demonstrated for SureChEMBL-to-PubChem).  Before 
we explore search examples we should examine the general question of what is the overall 
overlap between structures in papers and patents.  The commercial GOSTAR figure is that 
9% of compounds from papers are found in their patent extractions, indicating a slight rise 
from 6% in 2009 [6].  By contrast 18% of ChEMBL has a SureChEMBL match. There are 
two possible reasons for the higher number.  Firstly, ChEMBL subsumes ~0.5 million 
compounds from confirmed  Molecular Libraries Screening Centers Network (MLSCN) 
assays so this substantial increase in structures would be expected to increase in turn the 
number of literature extraction matches.  The second is that SureChEMBL extracts 
approximately three times the number of compounds GOSTAR does,  which should also 





We can approach the questions by looking at Q2.  A simple PubMed search with “BACE1 
inhibitor” brings up a relevant looking paper high in the result list (fig. 20). 
 
Figure 20.  The 4
th
 ranking match in PubMed with the query “BACE1 inhibitor” .  
This very recent paper (not yet captured by ChEMBL)  from Bristol-Meyers (BMS) has the 
hallmarks of a drug discovery team pursuing an orally available, brain penetrant BACE1 
inhibitor for which they already have activity in a mouse model.  The bonus for our question 
answering is that they have deposited two PDB structures containing ligands from the paper.  
Because the NCBI MMDB system assign a CID to PDB ligands where possible  the resulting 




Figure 21.  The connection between the publication PMID 27559936, the PDB entry 5KR8, 
the CID 90253397, the SureChEMBL SID 240769892 and the two family BMS patents 
above.  
While the BMS paper has good SAR characterisation for 18 structures in total [21],  the 
patent has cell based IC50 data for a series of 62 compounds that, with some manual 
engagement, can all be identified from the SureChEMBL output. Note also that 
WO2014098831 was picked up in the fig. 12 search but was a year further down the list.  Of 
the possible aproaches to Q1 perhaps the most effective is to download filtered patent 
chemistry from SureChEMBL and upload it to PubChem using the Indentifier Exchange 
Service.  The next step is to intersect these CIDs with ChEMBL.  Lead-like matches (i.e. not 
common chemistry) are likely to be from journal extractions at least two years or more after 
the patent date.    
Tracking back to first-filings 
 
This is a variation on the paper-to-patent Q2 but here the focus is searching backwards for the 
early patents on clinical candidates or recently approved drugs.  The special interest here is to 
possibly access patent SAR around a compound that has reached some level of success, even 
just in the preclinical stages.  One resource that enables making the appropriate connections 
is the IUPHAR/BPS Guide to PHARMACOLOGY (GtoPdb)  [22] .  Inspection of the 
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BACE1 entry indicates the expert curation of 15 lead compound and clinical candidates as 
ligand entries. For some of these patents have been curated into the reference where these 
were found to contain useful SAR.  A section from this panel is shown in fig. 22 and the 
SureChEMBL page shown in fig.23.  
 
Figure 22.  Snapshot from the GtoPdb page for BACE1 ligands.  The record for  verubecestat 
is expanded to show the pKi,  the patent reference in the lower panel, a live link to the 
SureChEMBL patent document and  identification of the example number as 25.  
 
Figure 23. The SureChEMBL page for verubecestat.  The lower set of green panels show the 
cross pointers to other databases mediated via UniChem, including  a GtoPdb link to fig. 22. 
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Note also if the 14 patent document hits are opened up we see Merck  WO2016053767 for 
“Novel crystalline forms of a bace inhibitor, compositions, and their use”  which was the 
secondary patent pointed out in fig.12.   
Given the verubecestat  compound  from Merck is now in Phase III it is somewhat unusual in 
not having any journal publications.  This, in this case the curation of a patent link into 
GtoPdb is particularly useful.  Although the discrete the SAR in US8940748 is minimal there 
are BACE1 and BACE2 Ki values.  Also somewhat unusually there are in the order of 200 
analogue structures full described without inhibition data but many with permeability 
measurements. N  Using the approaches described above most lead compounds and drugs, 
using GtoPdb or other resources as entry points,  can now be tracked back to their first-filings 
as novel structures, many of which include SAR.   
Conclusions and prospects  
 
It is hoped that the approaches and examples presented here will not only encourage but also 
enable medicinal chemists to dig SAR out of patents.  The recent “big bang” of patent 
chemistry flowing into public databases, alluded to above, now presents the best of both 
worlds situation in two senses.  This first is that the open patent data is becoming more 
synergistic with the features and content of commercial resources. The second is that those 
without access to the latter  are no longer constrained for SAR-digging even it may take a bit 
more time and effort.  So what of the future?  It would be useful to see comparative 
modelling results that might illuminate similarities and differences between data sources (i.e. 
could adding patent-only SAR improve models?)   
Other developments will include significant optimisation of the PubChem patent system in 
2017 (Evan Bolton, personal communication).  In addition, the development of patent 
information extraction systems continues (e.g.  the 2015 BioCreative V challenge “Chemical 
and Drug Named Entity Recognition from patent text” CHEMDNER patents [23]).  As an 
extension of these efforts both the commercial and open sectors are pursuing the holy grail of 
full automated D-A-R-C-P extraction using NLP and deep indexing approaches.  In 
conjunction we may also see “big data” scale patent processing initiatives  in the public 
domain.  These can exploit  Application Programming Interfaces (APIs) web services  (WS) 
and Resource Description Frameworks (RDF). These are already becoming  available for 
SureChEMBL as part of the OpenPHACTS initiative [24].    So might the major patent 
offices move towards fully electronic patent applications that would include XML full text, 
direct submission of chemical structures,  use of bioassay ontologies,  standardised data 
tables and bioentity identifiers for C07/A61 applications?  We’ll see  
Note added in proof:  As an important new development, in October 2016 the WIPO 
PATENTSCOPE portal (see website below) released a chemical structure search feature for ~ 
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SureChEMBL (large scale patent chemistry extraction) 
https://www.surechembl.org/search/ 
 
PubChem (92 million structures) 
https://pubchem.ncbi.nlm.nih.gov/ 
 
PubChem Identifier Exchange Service (mapping extrinsic chemistry into PubChem) 
https://pubchem.ncbi.nlm.nih.gov/idexchange/idexchange.cgi 
 
BindingDB (binding data for proteins and small molecules) 
http://bindingdb.org/bind/index.jsp 
 
ChEMBL (large scale literature extraction) 
https://www.ebi.ac.uk/chembl/ 
 




OSRA: Optical Structure Recognition Application (i2s) 
https://cactus.nci.nih.gov/osra/ 
 
OPSIN: Open Parser for Systematic IUPAC nomenclature (n2s) 
http://opsin.ch.cam.ac.uk/ 
 
ChemAxon Chemicalize, text processing  (n2s, with registration required) 
https://chemicalize.com/welcome 
 
IUPHAR/BPS Guide to PHARMACOLOGY (leads with patent connectivity) 
http://www.guidetopharmacology.org/ 
 
GOSTAR (Excelra Knowledge Solutions)  
http://www.excelra.com/gostar.php 
 
WIPO PATENTSCOPE database of 58 million documents 
http://www.wipo.int/patentscope/en/ 
 
European Patent Office (EPO) Espacenet database of 90 million documents 
https://worldwide.espacenet.com/ 
 
USPTO Patent Full-Text and Image Database 
https://www.uspto.gov/patents-application-process/search-patents 
 
International Patent Classification (IPC) 
http://www.wipo.int/classifications/ipc/en/ 
 
 
 
